C4 Therapeutics Presents Biomarker Data from New Myeloma Trials
C4 Therapeutics presented new biomarker reinforcing the immunomodulatory activity of cemsidomide in combination therapies at the 23rd IMS Annual Meeting, with data expected in Mid-2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed